Method of treatment or prevention of age-related macular degeneration

A technology related to macular degeneration, applied in pharmaceutical formulations, organic active ingredients, inorganic active ingredients, etc., can solve problems such as loss of central vision

Inactive Publication Date: 2008-09-10
DSM IP ASSETS BV
View PDF1 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Small blind spots can also occur in wet macular degeneration, causing loss of a person's central vision

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method of treatment or prevention of age-related macular degeneration

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0163] Buccal swabs were taken from adult individuals using a fiber brush or Q-tip. Buccal swabs were stored at 4°C until analysis. Buccal cells from this swab were used for DNA analysis and genotyping. DNA extraction was performed according to commercial suppliers (eg Qiagen Ltd, 8634 Hombrechtikon, Switzerland) using standard protocols such as "Isolation of DNA from buccal cells using the EZ1 DNA Tissue Kit (Qiagen Ltd, 8634 Hombrechtikon, Switzerland)". This protocol is designed for the isolation of total genomic and mitochondrial DNA from buccal cells. Genotypic analysis may involve different techniques, known to the skilled person and available through commercial services.

[0164] One or more of the following risk factor haplotypes may be included in the analysis:

[0165] Complement factor H SNP rslO61170, known as coding variant Y402H,

[0166] Angiotensin-converting enzyme lacking Alu repeats

[0167] Short-chain collagen CTRP-5 polymorphism at position Ser163Arg...

Embodiment 2

[0178] Buccal mucosa was swabbed from an individual (adult male, age 60, different from the individual in Example 1) and DNA was extracted as described in Example 1. This DNA was analyzed for SNP rs 106110, a coding mutant of Y402H, using primers and probes designed based on the sequence published in Haines et al, Science 308; 419 (2005). The adult was found to have the polymorphism and was recommended to receive a course of zeaxanthin at a dose of 12 mg / day, which was reduced to 6 mg / day after one month.

Embodiment 3

[0180] A 6 milliwatt, 0.5 mm argon laser spot (488 or 514 nm) was aimed for 9 seconds at the fovea of ​​a plate-mounted human retina from a 65-year-old human female. The scattered laser light is collected and analyzed by a commercially available grating monochromator (eg Spex Triple-mate) using a cryogenically cooled CCD array. Signal intensity calibration for actual carotenoid levels was accomplished by examining human postmortem eyes.

[0181] A characteristic strong Raman spectrum of macular carotenoids was observed in the fovea, superimposed on top of a weak fluorescent background. As the laser spot was centrifugally removed from the fovea, the Raman spectrum began to fade gradually. The intensity of the Raman signal decreased by a factor of at least 20 when the laser was 3 mm from the fovea. The patient was prescribed a course of lutein at a dose of 12 mg / day.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A method of treatment and / or prevention of age-related macular degeneration (AMD) wherein, in a first step, the need for treatment or susceptibility to AMD is determined for an individual and, in a second step, a medication comprising lutein and / or zeaxanthin and / or certain antioxidants (or a mixture thereof) is tailored to that individual. The invention also provides a method of determining a substance to be administered to an individual, which individual may be susceptible of having age-related macular degeneration (or an age-related macular degeneration-related disorder) comprising: a) determining the susceptibility of the individual to age-related macular degeneration (usually genetically, by detection of an SNP); and b) on the basis of the determination in a), identifying a substance capable of preventing or treating age-related macular degeneration in that individual. The method may additionally comprise providing (such as administering or communicating) the substance (or its identity) to the individual.

Description

technical field [0001] The present invention relates to novel methods for (treatment and / or) prevention of Age related Macular Degeneration (AMD). It involves diagnosing and / or treating age-related macular degeneration in an individual (or subject) by determining the individual's susceptibility to age-related macular degeneration and selecting or identifying (and administering) a substance for the individual based on the determination ( or age-related macular degeneration). technical background [0002] The most common cause of vision loss in people over the age of 60, macular degeneration affects millions of older adults each year. The disease affects central vision, sometimes making it difficult to read, drive, or perform activities that require good, detailed vision. When the macula is destroyed, the eye loses its ability to see fine details such as small print, facial features, or small objects. Damaged parts of the macula often cause scotomas or are located in areas ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/047A61K31/375A61K31/355A61K33/30A61K33/34A61P27/02
CPCA61K31/047A61K31/355A61K33/30A61K31/375A61K33/34A61P27/02A61K2300/00A61K31/01
Inventor 瑞吉纳·古拉尔奇克安托恩·德赛茨厄沃格方格·斯沙赫伊戈尔·本迪克
Owner DSM IP ASSETS BV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap